FlandersBio on Twitter

Follow us on Twitter

Life sciences database

Databank life sciences

in het nederlands in english

FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.

FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.

TiGenix

Website: http://www.tigenix.com
Email:
Phone: +32 16 39 60 60
FlandersBio Member
More address details

Business Focus

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with one product on the market and a strong clinical stage pipeline of adult stem cell programs. The company's lead product, ChondroCelect®, for cartilage repair in the knee, is the first product to be approved and obtain national reimbursement in Europe. ChondroCelect is currently on the market in Belgium, the Netherlands, Spain, the UK and Finland and benefits from full national reimbursement in 3 of these countries.

Tags

Company Profile

TiGenix's stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. TiGenix’ eASC pipeline comprises 3 clinical stage assets:

  • Cx601: In European Phase III for the treatment of fistulising Crohn’s. Positive pre-IND for US development completed
  • Cx611: Phase IIa completed in R
  • Cx621: Phase I completed

TiGenix is based out of Leuven (Belgium), and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).

Product description

ChondroCelect®

ChondroCelect, the company’s product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, through clinical development to central European registration as a medicinal product. ChondroCelect consists of characterized cultured chondrocytes derived from the patient’s own cartilage and is used for autologous chondrocyte implantation (ACI), a surgical procedure to treat cartilage defects. ChondroCelect received European marketing authorisation as the first Advanced Therapy Medicinal Product, indicated for repair of single symptomatic cartilage defects of the femoral condyle of the knee in adults.

More info

Address: Romeinse straat 12 bus 2
3001 Leuven
Belgium

Route: Via Google Maps
Website: http://www.tigenix.com

Phone: +32 16 39 60 60
Fax: +32 16 39 60 70
Foundation date: 1/2000
Email: info@tigenix.com

Become a Member

Listen to some testimonials from companies that are a member of FlandersBio and discover the benefits of membership

Read more

Biotechstockmarket

Belgian biotech on Euronext

Belgian biotech on Euronext

FlandersBio Members

Beta-Cell Jalima Pharma Antwerp University Hospital Fern Valley IMS Health Q-Biologicals Korys Nederlandsch Octrooibureau Vision4Care Medicim Intellicrops Biocartis Cardio3 BioSciences Emtex Balans Laboratorium Domobios Merck Millipore Apitope International Deloitte Amgen AnaBioTec Arenco Pharmaceutica Pall Belgium PhaRA Viziphar Biosciences Genzyme DROIA CNA Insurance Company Ltd Arcarios Galapagos

View all members

Life Sciences Map

Life Sciences Map

View Life Sciences Map

Back to top

Print